A groundbreaking step in the fight against cholera is underway, as a South African company embarks on a mission to develop a new oral vaccine. But is it too little, too late for a continent in crisis?
Biovac, a biopharmaceutical pioneer, has initiated clinical trials for an oral cholera vaccine, marking the first such trial in half a century. This development comes at a critical time when Africa is grappling with a devastating cholera surge. The continent bears a staggering burden, accounting for a whopping 82% of global cholera cases and an even more alarming 93.5% of cholera-related deaths, according to the Africa Centres for Disease Control and Prevention (Africa CDC).
The urgency of the situation is evident. In just the first 10 months of 2025, over 297,000 cholera cases and nearly 7,000 deaths were reported across 23 African countries. And the crisis is far from over. But here's where it gets controversial: the global supply of oral cholera vaccines is woefully inadequate to meet the demand, especially in Africa.
Africa CDC Director General Jean Kaseya highlighted the stark disparity in vaccine availability. While the continent requires 80 million doses, the global supply stands at a mere 15 to 18 million. This shortage has left many African countries in a desperate situation, unable to secure the necessary vaccines. For instance, Zimbabwe needs 3.2 million doses but received only 800,000, and the Democratic Republic of Congo (DRC) faces an even more dire shortage.
Biovac's new development laboratory in Cape Town, inaugurated just days before the trial announcement, is a beacon of hope. The facility boasts the capability to manage the entire vaccine production process, from initial development to final manufacturing. It is even equipped to handle cutting-edge technologies like messenger RNA. This investment aligns with the African Union's ambitious goal of locally producing 60% of the vaccines used on the continent by 2040, a significant leap from the current 1%.
The successful development and market launch of Biovac's oral cholera vaccine could be a game-changer, expanding the company's portfolio beyond its current offerings for tuberculosis, tetanus, diphtheria, poliomyelitis, and hepatitis B. But the road ahead is fraught with challenges, as the company must navigate the complexities of vaccine development and the urgency of a public health crisis.
As Biovac's trial progresses, the world watches with bated breath. Will this initiative be the turning point in Africa's battle against cholera? Or will the continent continue to grapple with this deadly disease? The answers lie in the coming years, as Biovac's efforts unfold. And this is the part most people miss: the impact of this trial extends far beyond the laboratory, potentially shaping the future of vaccine production and public health in Africa.
